对于三方交叉生物等价性研究的多重性调整方法
David Hinds1, Stella Grosser1, Wanjie Sun1
1Center for Drug Evaluation and Research, Silver Spring, MD, USA.
Pharmaceutical statistics
|March 11, 2026
概括
本研究引入了用于控制仿制药生物等价性 (BE) 测试中的统计学意义的改进方法. 修订后的Bonferroni,Holm和Hochberg方法在三向交叉BE研究中提高了功率并减少了样本大小.
科学领域:
- 药理动力学和药物开发
- 生物统计学 生物统计学
- 监管科学 监管科学
背景情况:
- 通用药物生物等价性 (BE) 研究通常使用三向交叉设计,将两个通用 (T) 与一个参考 (R) 配方进行比较.
- 同等性测试中的多重性调整研究不足,监管机构的指导有限,如ICH M13A.
研究的目的:
- 评估传统的多重性调整方法进行等效测试.
- 为三向交叉生物等价性研究提出和评估修订后的多重性调整方法.
主要方法:
- 修订了Bonferroni,Holm和Hochberg方法,应用于p值和置信区间.
- 在模拟中纳入"一次两次"规则和测试统计数据之间的相关性.
- 与现有的多重性控制方法和两个单独的双向交叉研究进行比较.
主要成果:
- 与进行两个单独的双向交叉研究相比,提出的方法显著提高了统计能力,并减少了样本大小.
- 家庭智能错误率控制在所需的水平.
- 与没有阿尔法调整的分析相比,所需的样本大小仅略有增加.
结论:
- 修订后的邦费罗尼,霍尔姆或霍赫伯格方法被推用于对比两种仿制药和一种参考药物的三向交叉生物等价性研究.
- 这些方法在仿制药开发中为多重性控制提供了一种强大且统计学上合理的方法.
相关概念视频
Bioequivalence Experimental Study Designs: Repeated Measures, Cross-Over, Carry-Over, and Latin Square Designs
359
Bioequivalence experimental study designs play a pivotal role in testing the effectiveness of various treatments. Key among these are the repeated measures, cross-over, carry-over, and Latin square designs. In the repeated measures design, each subject receives all treatments, allowing for temporal comparisons. This type of design is useful in reducing variability but requires careful planning to avoid bias.The cross-over design, an economical method, involves sequential administration of...
359
Crossover Experiments
4.7K
Crossover experiments, also called the repeated-measurements design, is a study design in which all experimental units are exposed to all treatments in different periods. Crossover experiments are generally used in psychology, the pharmaceutical industry, agriculture, and medicine.
Crossover designs are performed even with smaller sample sizes since the samples can act as their controls. These are better than simple randomized trials since patients are exposed to all the treatments.
Crossover designs are performed even with smaller sample sizes since the samples can act as their controls. These are better than simple randomized trials since patients are exposed to all the treatments.
4.7K
Bioequivalence Experimental Study Designs: Completely Randomized and Randomized Block Designs
348
Bioequivalence experimental study designs are crucial methodologies used in evaluating and comparing the bioavailability of different drug products. These designs are categorized into various types: completely randomized, randomized block, repeated measures, cross and carry-over, and Latin square designs.Completely randomized designs involve randomly allocating treatments to all subjects participating in the experiment. This allocation is achieved by assigning unique random numbers to subjects...
348
Bioavailability Study Design: Single Versus Multiple Dose Studies
305
Bioavailability studies are essential for understanding how a drug is absorbed, distributed, metabolized, and excreted in the body. These studies assess the extent and rate at which the active pharmaceutical agent becomes available at the site of action. The design of bioavailability studies can involve single-dose or multiple-dose regimens, each with distinct advantages and limitations.Single-dose studies are the preferred approach due to their simplicity and reduced drug exposure for...
305
Bioequivalence studies: Biowaivers
364
In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
364
Bioequivalence: Overview
2.1K
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
2.1K


